Answers are grounded in this paper and cite their sources.
Loading...
Clinical trial demonstrates no significant cardiovascular risk reduction with atorvastatin in hemodialysis patients with diabetes, highlighting complex disease mechanisms.
Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Wanner et al. (2005) studied this question.